Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ArriVent BioPharma, Inc. (AVBP) and Encourages Stockholders to Learn More About the Investigation

By ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ArriVent BioPharma, Inc. ("ArriVent" or "the Company") (NASDAQ:AVBP). Investors who purchased ArriVent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/arrivent-biopharma-inc-avbp-investigation.

ArriVent Investigation Details

On October 6, 2026, ArriVent BioPharma, Inc. announced that its global Phase 3 FURVENT trial evaluating firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer failed to meet its primary endpoint of progression-free survival. Previously, the Company had stated in a November 10, 2025 filing that no interim analysis had been conducted or was planned, and subsequently filed a May 11, 2026 prospectus supporting an at-the-market offering of up to $250 million while describing its ongoing Phase 3 trial. The investigation concerns whether ArriVent adequately disclosed information regarding the trial's progress and the timing of any negative efficacy data. Following the October 6 announcement, ArriVent's stock price declined approximately 50%-63% during the trading session, reaching a 52-week low of approximately $12.09.

What's Next for ArriVent Investors?

If you are aware of any facts relating to this investigation or purchased ArriVent securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/arrivent-biopharma-inc-avbp-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to ArriVent Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for ArriVent Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.